CL2021000596A1 - (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de uso - Google Patents
(r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de usoInfo
- Publication number
- CL2021000596A1 CL2021000596A1 CL2021000596A CL2021000596A CL2021000596A1 CL 2021000596 A1 CL2021000596 A1 CL 2021000596A1 CL 2021000596 A CL2021000596 A CL 2021000596A CL 2021000596 A CL2021000596 A CL 2021000596A CL 2021000596 A1 CL2021000596 A1 CL 2021000596A1
- Authority
- CL
- Chile
- Prior art keywords
- carbamoylpyridin
- trifluoromethoxy
- piperazine
- carboxylate
- benzyl
- Prior art date
Links
- XXDVCULQMDDOAX-CYBMUJFWSA-N (5-carbamoylpyridin-3-yl) (2R)-2-methyl-4-[[3-(trifluoromethoxy)phenyl]methyl]piperazine-1-carboxylate Chemical compound O(C(F)(F)F)C1=CC=CC(CN2C[C@H](N(CC2)C(=O)OC2=CC(C(=O)N)=CN=C2)C)=C1 XXDVCULQMDDOAX-CYBMUJFWSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente, se proporcionan formas cristalinas de (R)-5-carbamoilpiridin-3-il-2-metil-4-(3-<br /> (trifluorometoxi)bencil)piperazin-1-carboxilato. También se describen composiciones farmacéuticas que comprenden formas cristalinas de (R)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731014P | 2018-09-13 | 2018-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000596A1 true CL2021000596A1 (es) | 2021-07-30 |
Family
ID=68069873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000596A CL2021000596A1 (es) | 2018-09-13 | 2021-03-10 | (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de uso |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11053199B2 (es) |
| EP (2) | EP4434583A2 (es) |
| JP (1) | JP7405840B2 (es) |
| KR (1) | KR20210057789A (es) |
| CN (3) | CN113227069B (es) |
| AU (1) | AU2019337623A1 (es) |
| BR (1) | BR112021004340A2 (es) |
| CA (1) | CA3112200A1 (es) |
| CL (1) | CL2021000596A1 (es) |
| CO (1) | CO2021003295A2 (es) |
| DK (1) | DK3849970T3 (es) |
| EA (1) | EA202190511A1 (es) |
| FI (1) | FI3849970T3 (es) |
| IL (1) | IL281276B1 (es) |
| LT (1) | LT3849970T (es) |
| MA (1) | MA53607A (es) |
| MX (1) | MX2021002923A (es) |
| PT (1) | PT3849970T (es) |
| RS (1) | RS65967B1 (es) |
| SG (1) | SG11202102143RA (es) |
| WO (1) | WO2020056105A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI385152B (zh) | 2005-02-17 | 2013-02-11 | Astellas Pharma Inc | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (I) |
| EP3099332A4 (en) * | 2014-01-29 | 2017-06-21 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| CA3056076A1 (en) | 2017-03-13 | 2018-09-20 | Abide Therapeutics, Inc. | A substituted-heterocyclic-c(o)o-(substituted pyridin-3-yl)compound and its use as a dual magl and faah inhibitor |
-
2019
- 2019-09-12 EP EP24185102.1A patent/EP4434583A2/en active Pending
- 2019-09-12 IL IL281276A patent/IL281276B1/en unknown
- 2019-09-12 MX MX2021002923A patent/MX2021002923A/es unknown
- 2019-09-12 CN CN201980060119.9A patent/CN113227069B/zh active Active
- 2019-09-12 MA MA053607A patent/MA53607A/fr unknown
- 2019-09-12 CN CN202410683425.0A patent/CN118561814A/zh active Pending
- 2019-09-12 FI FIEP19778721.1T patent/FI3849970T3/fi active
- 2019-09-12 BR BR112021004340-3A patent/BR112021004340A2/pt unknown
- 2019-09-12 SG SG11202102143RA patent/SG11202102143RA/en unknown
- 2019-09-12 CN CN202410683444.3A patent/CN118530218A/zh active Pending
- 2019-09-12 CA CA3112200A patent/CA3112200A1/en active Pending
- 2019-09-12 US US16/569,578 patent/US11053199B2/en active Active
- 2019-09-12 DK DK19778721.1T patent/DK3849970T3/da active
- 2019-09-12 RS RS20241039A patent/RS65967B1/sr unknown
- 2019-09-12 JP JP2021514123A patent/JP7405840B2/ja active Active
- 2019-09-12 KR KR1020217010747A patent/KR20210057789A/ko not_active Application Discontinuation
- 2019-09-12 AU AU2019337623A patent/AU2019337623A1/en active Pending
- 2019-09-12 EP EP19778721.1A patent/EP3849970B1/en active Active
- 2019-09-12 PT PT197787211T patent/PT3849970T/pt unknown
- 2019-09-12 WO PCT/US2019/050771 patent/WO2020056105A1/en active Application Filing
- 2019-09-12 LT LTEPPCT/US2019/050771T patent/LT3849970T/lt unknown
- 2019-09-12 EA EA202190511A patent/EA202190511A1/ru unknown
-
2021
- 2021-03-10 CL CL2021000596A patent/CL2021000596A1/es unknown
- 2021-03-12 CO CONC2021/0003295A patent/CO2021003295A2/es unknown
- 2021-06-03 US US17/338,182 patent/US11680046B2/en active Active
-
2023
- 2023-05-05 US US18/143,765 patent/US20230382861A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4434583A2 (en) | 2024-09-25 |
| CA3112200A1 (en) | 2020-03-19 |
| PT3849970T (pt) | 2024-09-25 |
| CO2021003295A2 (es) | 2021-07-30 |
| MA53607A (fr) | 2021-12-22 |
| US11053199B2 (en) | 2021-07-06 |
| LT3849970T (lt) | 2024-10-10 |
| WO2020056105A1 (en) | 2020-03-19 |
| RS65967B1 (sr) | 2024-10-31 |
| CN113227069B (zh) | 2024-11-05 |
| KR20210057789A (ko) | 2021-05-21 |
| EP3849970B1 (en) | 2024-07-03 |
| AU2019337623A1 (en) | 2021-05-13 |
| JP7405840B2 (ja) | 2023-12-26 |
| CN118530218A (zh) | 2024-08-23 |
| BR112021004340A2 (pt) | 2021-05-25 |
| SG11202102143RA (en) | 2021-04-29 |
| US20230382861A1 (en) | 2023-11-30 |
| US11680046B2 (en) | 2023-06-20 |
| EP3849970A1 (en) | 2021-07-21 |
| FI3849970T3 (fi) | 2024-09-20 |
| IL281276B1 (en) | 2024-09-01 |
| EA202190511A1 (ru) | 2021-07-05 |
| US20210363105A1 (en) | 2021-11-25 |
| CN113227069A (zh) | 2021-08-06 |
| WO2020056105A9 (en) | 2020-07-09 |
| JP2022500441A (ja) | 2022-01-04 |
| US20200095201A1 (en) | 2020-03-26 |
| CN118561814A (zh) | 2024-08-30 |
| MX2021002923A (es) | 2021-09-08 |
| DK3849970T3 (da) | 2024-09-30 |
| IL281276A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
| CO2019002596A2 (es) | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CR20200483A (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
| CL2017003240A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
| CL2021000855A1 (es) | Replicones basados en alfavirus para la administración de bioterapias. | |
| CL2021002656A1 (es) | Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso. | |
| BR112017017411A2 (pt) | Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida | |
| ECSP21068097A (es) | Anticuerpos claudina 6 y usos de los mismos | |
| ECSP21021189A (es) | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso | |
| AR119997A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
| BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
| BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
| CR20160392A (es) | Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de esta | |
| BR112022010143A2 (pt) | Inibidores de ahr e usos respectivos | |
| UY38759A (es) | Tienilhidroxiisoxazolinas y derivados de las mismas | |
| CO2019011980A2 (es) | Formas cristalinas de (s)-afoxolaner | |
| CL2019003167A1 (es) | Proteínas de unión al antígeno anti-jagged1. | |
| SV2019005811A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
| AR111431A1 (es) | Combinaciones de fungicidas | |
| CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 | |
| CL2021000596A1 (es) | (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de uso | |
| CL2021002501A1 (es) | Compuestos novedosos y métodos de uso de los mismos. |